Velocity
This Week's Stories
Stipple Bio

Stipple Bio

Biotech · Oncology · Pharma

Partnership

Eli Lilly signs $5.9B oncology deal with biotech Stipple Bio

November 16, 2026

Epitope-level targeting could unlock cancer markers too risky for today's precision therapies to touch, if the science holds.

  • Eli Lilly signed a strategic oncology research collaboration and license agreement with Stipple Bio worth up to $5.9 billion in milestone payments, plus an upfront payment and equity stake.
  • Stipple Bio, a Cambridge, Mass. biotech co-founded by Fred Hutch's Aaron Ring and UCSF's Aashish Manglik, uses its Pointillist platform to find cancer-specific cell-surface epitopes.
  • Lilly secures exclusive worldwide rights to develop and commercialize any products arising from the collaboration, which spans multiple undisclosed modalities and indications.
  • Stipple raised a $100 million Series A in April, giving it cash runway into 2029 as it independently advances its own pipeline alongside the Lilly work.
  • Stipple's own lead candidate, antibody-drug conjugate STP-100 for solid tumors including pancreatic cancer, is slated to enter Phase 1 trials in early 2027.
  • The pact extends Lilly's oncology push beyond blockbusters Verzenio and Jaypirca as the drugmaker diversifies beyond its diabetes and obesity franchise.
  • By targeting epitopes unique to tumor cells rather than broadly overexpressed proteins, Stipple's approach could open up drug targets long avoided due to toxicity in healthy tissue.

Get the app

Stay Ahead With Velocity

Deep company profiles, investor context, and every original source behind this story — plus the next one, the moment it breaks.

Download on the App StoreGet it on Google Play

More This Week

View All →